A lab technician and blogger writes about "reading into" a principal investigator's choice of which lab member attends invitation-only meetings. "Not being a PI, I can only assume what the rationale might be behind the decision to involve a certain trainee over another in a certain process," the author writes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.